T. Rowe Price Associates
AUTL

T. Rowe Price Associates’s Autolus Therapeutics AUTL Stock Holding History

T. Rowe Price Associates’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,694,202
Closed -$6.14M – 3049
2025
Q2 		$6.14M Sell
2,694,202
-205,984
-7% -$341K ﹤0.01% 1223
2025
Q1 		$4.5M Sell
2,900,186
-39,055
-1% -$79.3K ﹤0.01% 1282
2024
Q4 		$6.91M Sell
2,939,241
-902,261
-23% -$3.05M ﹤0.01% 1206
2024
Q3 		$13.9M Sell
3,841,502
-572,585
-13% -$2.28M ﹤0.01% 1072
2024
Q2 		$15.4M Sell
4,414,087
-1,074,899
-20% -$4.64M ﹤0.01% 1022
2024
Q1 		$35M Buy
5,488,986
+2,487,778
+83% +$15.5M ﹤0.01% 820
2023
Q4 		$19.3M Buy
+3,001,208
New +$11.4M ﹤0.01% 967
2020
Q1 		– Sell
-941,500
Closed -$12.4M – 2514
2019
Q4 		$12.4M Sell
941,500
-208,229
-18% -$2.73M ﹤0.01% 1277
2019
Q3 		$14.3M Sell
1,149,729
-30,667
-3% -$405K ﹤0.01% 1236
2019
Q2 		$19M Buy
1,180,396
+645,879
+121% +$14.4M ﹤0.01% 1191
2019
Q1 		$16.8M Buy
534,517
+32,977
+7% +$938K ﹤0.01% 1227
2018
Q4 		$16.5M Sell
501,540
-1,221
-0.2% -$40.2K ﹤0.01% 1201
2018
Q3 		$15.2M Buy
502,761
+2,761
+0.6% +$74.5K ﹤0.01% 1300
2018
Q2 		$13.4M Buy
+500,000
New +$13.2M ﹤0.01% 1292

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates's AUTL Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 2,694,202 shares — an estimated $6.14M sold.

T. Rowe Price Associates first reported a position in AUTL in Q2 2018 and held it in 14 quarters. The position peaked at $35M in Q1 2024. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,694,202 Autolus Therapeutics shares in Q3 2025, an estimated $6.14M.
  • T. Rowe Price Associates first reported a position in Autolus Therapeutics in Q2 2018 and held it in 14 quarters.
  • T. Rowe Price Associates's Autolus Therapeutics position peaked at $35M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.